Partnerships

 
Corporate video

Partnering with us

At Palau, partnering plays a strong role in both our business model and our development philosophy. We believe that the key to success is forming complementary partnerships that are defined by strong commitment, close collaboration and transparent communication.

Firms interested in partnering with Palau will find that we present a variety of strengths and benefits, including:

  • Commitment and close collaboration in working with licensees and licensors
  • Proven record of successful alliances
  • Over 100 years of collective research and clinical development experience
  • An enthusiastic and dedicated management team
  • A scientific team acquainted with US and EU regulatory requirements
  • Experienced Quality Assurance unit that ensures GLP, GSP and GCP compliance
  • State-of-the-art facilities

We are actively building networks and pursuing innovative, creative and value-driven alliances with pharmaceutical and biotechnology companies around the world.  Our goal is to create value for all stakeholders in the development of new drugs, including patients and health care professionals.

CO-DISCOVERY AND DEVELOPMENT OPPORTUNITIES

 

Palau is seeking collaborations with leading biotechnology and pharmaceutical companies on early ongoing as well as new programs. Of particular interest are targets and indications in the inflammatory, autoimmune and respiratory fields.

 

IN-LICENSING AND COLLABORATION OPPORTUNITIES

 

For companies that have their own products in development, Palau offers the opportunity to collaborate with a highly experienced clinical development team.

Currently, we are actively seeking to establish relationships with companies interested in out-licensing their patent-protected New Chemical Entities or New Formulation projects. We are especially interested in compounds that have reached the late preclinical stage or early Phase I clinical trials. The therapeutic fields of greatest interest are diseases of inflammatory and autoimmune origin, such as asthma, psoriasis and rheumatoid arthritis. We are also open to evaluating opportunities in other therapeutic areas.

PDF. Ideal project in-licensing profile
 

OUT-LICENSING OPPORTUNITIES

 

Our product pipeline currently consists of several projects at various stages of development, each addressing novel targets.  Generally, Palau considers out-licensing after having completed at least one Phase II clinical trial (proof-of-concept). However, we are also open to the possibility of establishing partnerships and collaborative agreements at earlier stages of development, as we have successfully done in the past.

 

For more information about our projects or for in-licensing opportunities, please Contact Us